{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:05:10Z","timestamp":1793300710735,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.03.065","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T21:18:33Z","timestamp":1711660713000},"page":"2983-2993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-6424","authenticated-orcid":false,"given":"Lindsay R.","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-0211","authenticated-orcid":false,"given":"Germaine","family":"Hanquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4822-8434","authenticated-orcid":false,"given":"Ingrid T.","family":"Sep\u00falveda-Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9202","authenticated-orcid":false,"given":"Christian","family":"Theilacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-551X","authenticated-orcid":false,"given":"Marc","family":"Baay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary P.E.","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Jodar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-7194","authenticated-orcid":false,"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.03.065_b0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/cis691","article-title":"Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger","volume":"55","author":"McEllistrem","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0010","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/JCM.02199-06","article-title":"Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae","volume":"45","author":"Park","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.065_b0015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1086\/593339","article-title":"Differential effects of pneumococcal vaccines against serotypes 6A and 6C","volume":"198","author":"Park","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0020","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1128\/IAI.00510-07","article-title":"Genetic basis for the new pneumococcal serotype, 6C","volume":"75","author":"Park","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.03.065_b0025","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0140-6736(06)69637-2","article-title":"Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study","volume":"368","author":"Whitney","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.03.065_b0030","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/INF.0000000000000728","article-title":"Efficacy of the 7-valent pneumococcal conjugate vaccine against acute otitis media caused by serotype 6C pneumococcus","volume":"34","author":"Palmu","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.03.065_b0035","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/civ067","article-title":"Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era","volume":"60","author":"Kaplan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0040","doi-asserted-by":"crossref","first-page":"e0177113","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0045","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/14760584.2019.1688149","article-title":"Serotype evolution in Western Europe: perspectives on invasive pneumococcal diseases (IPD)","volume":"18","author":"Tin Tin Htar","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.065_b0050","doi-asserted-by":"crossref","first-page":"e72743","DOI":"10.1371\/journal.pone.0072743","article-title":"Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccines","volume":"8","author":"Benfield","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0055","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.vaccine.2016.04.043","article-title":"The impact of pneumococcal conjugate vaccines on carriage of and disease caused by Streptococcus pneumoniae serotypes 6C and 6D in southern Israel","volume":"34","author":"Porat","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0060","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1016\/j.vaccine.2015.08.010","article-title":"A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation","volume":"33","author":"Cohen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0065","doi-asserted-by":"crossref","first-page":"e90935","DOI":"10.1371\/journal.pone.0090935","article-title":"Clonal expansion of the macrolide resistant ST386 within pneumococcal serotype 6C in France","volume":"9","author":"Janoir","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0070","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/JCM.01984-08","article-title":"Temporal trends and molecular epidemiology of recently described serotype 6C of Streptococcus pneumoniae","volume":"47","author":"Nunes","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.065_b0075","doi-asserted-by":"crossref","unstructured":"Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis 2013; 19: 1074\u201383.","DOI":"10.3201\/eid1907.121830"},{"key":"10.1016\/j.vaccine.2024.03.065_b0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1473-3099(20)30489-8","article-title":"The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006\u201317): a multicentre, retrospective observational study","volume":"21","author":"Agudelo","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0085","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1128\/JCM.01919-08","article-title":"PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007","volume":"47","author":"Carvalho Mda","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.065_b0090","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/jac\/dkr193","article-title":"Trends of invasive serotype 6C pneumococci in Spain: emergence of a new lineage","volume":"66","author":"Rolo","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2024.03.065_b0095","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.vaccine.2019.06.071","article-title":"Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006\u20132018","volume":"37","author":"Andrews","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0100","doi-asserted-by":"crossref","first-page":"e0161257","DOI":"10.1371\/journal.pone.0161257","article-title":"Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two Years of age in Germany","volume":"11","author":"van der Linden","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0105","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0110","doi-asserted-by":"crossref","first-page":"e74906","DOI":"10.1371\/journal.pone.0074906","article-title":"Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes","volume":"8","author":"Grant","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0115","doi-asserted-by":"crossref","unstructured":"Garcia Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, et al. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10\/13 Period: Findings from the PSERENADE Project. Microorganisms 2021; 9.","DOI":"10.3390\/microorganisms9040738"},{"key":"10.1016\/j.vaccine.2024.03.065_b0120","doi-asserted-by":"crossref","first-page":"1872341","DOI":"10.1080\/21645515.2021.1872341","article-title":"Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease","volume":"18","author":"Izurieta","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.03.065_b0125","unstructured":"International Vaccine Access Center. Pneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME). Summary of Findings from Systematic Review. Available from: https:\/\/terrance.who.int\/mediacentre\/data\/sage\/SAGE_Docs_Ppt_Oct2017\/9_session_PCV\/Oct2019_session9_PCV_PRIMEsummary.pdf."},{"key":"10.1016\/j.vaccine.2024.03.065_b0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/10543400600719236","article-title":"Overview of vaccine field studies: types of effects and designs","volume":"16","author":"Halloran","year":"2006","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.vaccine.2024.03.065_b0135","doi-asserted-by":"crossref","first-page":"5634","DOI":"10.1016\/j.vaccine.2013.07.006","article-title":"Vaccine effects and impact of vaccination programmes in post-licensure studies","volume":"31","author":"Hanquet","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0140","unstructured":"World Health Organization = Organisation mondiale de la S. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013February 2019 \u2500 Vaccins antipneumococciques conjugu\u00e9s chez les nourrissons et les enfants de moins de 5 ans: note de synth\u00e8se de l\u2019OMS \u2013 f\u00e9vrier 2019. Weekly Epidemiol Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 2019; 94: 85\u2013103."},{"key":"10.1016\/j.vaccine.2024.03.065_b0145","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/ciy129","article-title":"Effectiveness of 7- and 13-valent pneumococcal conjugate vaccines in a schedule without a booster dose: a 10-Year observational study","volume":"67","author":"Jayasinghe","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0150","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.vaccine.2022.05.011","article-title":"Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study","volume":"40","author":"Savulescu","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0155","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0160","doi-asserted-by":"crossref","first-page":"e0163269","DOI":"10.1371\/journal.pone.0163269","article-title":"Nasopharyngeal pneumococcal Carriage among healthy children in Cyprus post widespread simultaneous implementation of PCV10 and PCV13 vaccines","volume":"11","author":"Hadjipanayis","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0165","doi-asserted-by":"crossref","first-page":"e0262466","DOI":"10.1371\/journal.pone.0262466","article-title":"Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent pneumococcal conjugate vaccine (PCV10) introduction in Pakistan","volume":"17","author":"Nisar","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0170","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/14760584.2020.1853533","article-title":"Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials","volume":"19","author":"Nunes","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.03.065_b0175","doi-asserted-by":"crossref","unstructured":"Latasa Zamalloa P, Sanz Moreno JC, Ordob\u00e1s Gav\u00edn M, Barranco Ordo\u00f1ez MD, Ins\u00faa Marisquerena E, Gil de Miguel \u00c1, et al. Trends of invasive pneumococcal disease and its serotypes in the Autonomous Community of Madrid. Enferm Infecc Microbiol Clin (Engl Ed) 2018; 36: 612\u201320.","DOI":"10.1016\/j.eimce.2018.07.007"},{"key":"10.1016\/j.vaccine.2024.03.065_b0180","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.anpedi.2021.05.018","article-title":"Invasive pneumococcal disease in children under 60 months before and after availability of 13-valent conjugate vaccine","volume":"96","author":"Mart\u00ednez-Osorio","year":"2022","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.vaccine.2024.03.065_b0185","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/cid\/cix685","article-title":"Comparison of the impact of pneumococcal conjugate vaccine 10 or pneumococcal conjugate vaccine 13 on invasive pneumococcal disease in equivalent populations","volume":"65","author":"Naucler","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/cid\/ciw720","article-title":"Long-term impact of a \u201c3 + 0\u201d schedule for 7- and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in Australia, 2002\u20132014","volume":"64","author":"Jayasinghe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0195","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(18)30052-5","article-title":"Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000\u201317: a prospective national observational cohort study","volume":"18","author":"Ladhani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0200","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/INF.0000000000001207","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal Carriage among American Indians","volume":"35","author":"Grant","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.03.065_b0205","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jpids\/piaa035","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease after introduction into routine pediatric use","volume":"10","author":"Baxter","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.vaccine.2024.03.065_b0210","doi-asserted-by":"crossref","first-page":"e0175224","DOI":"10.1371\/journal.pone.0175224","article-title":"Decrease of invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal 13-valent conjugate vaccine in Spain","volume":"12","author":"C\u00e0mara","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0215","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cmi.2019.10.034","article-title":"Emerging non-13-valent pneumococcal conjugate vaccine (PCV13) serotypes causing adult invasive pneumococcal disease in the late-PCV13 period in Spain","volume":"26","author":"Gonz\u00e1lez-D\u00edaz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2024.03.065_b0220","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.vaccine.2017.03.031","article-title":"The herd effects of infant PCV7\/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel","volume":"35","author":"Regev-Yochay","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0225","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1017\/S0950268817001194","article-title":"The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era. Has there been a herd effect?","volume":"145","author":"Corcoran","year":"2017","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.03.065_b0230","doi-asserted-by":"crossref","first-page":"e0239848","DOI":"10.1371\/journal.pone.0239848","article-title":"Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: a retrospective cohort study","volume":"15","author":"Vadlamudi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.03.065_b0235","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1016\/j.vaccine.2015.07.080","article-title":"Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska","volume":"33","author":"Bruce","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0240","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1016\/j.vaccine.2018.05.026","article-title":"The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage","volume":"36","author":"Ciruela","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0245","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","article-title":"Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm","volume":"47","author":"Galanis","year":"2016","journal-title":"Sweden Eur Respir J"},{"key":"10.1016\/j.vaccine.2024.03.065_b0250","doi-asserted-by":"crossref","unstructured":"Oyewole OR, Lang P, Albrich WC, Wissel K, Leib SL, Casanova C, et al. The impact of Pneumococcal Conjugate Vaccine (PCV) coverage heterogeneities on the changing epidemiology of invasive pneumococcal disease in Switzerland, 2005-2019. Microorganisms 2021; 9.","DOI":"10.3390\/microorganisms9051078"},{"key":"10.1016\/j.vaccine.2024.03.065_b0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2020.11.018","article-title":"Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands","volume":"39","author":"Peckeu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0260","doi-asserted-by":"crossref","first-page":"6558","DOI":"10.1016\/j.vaccine.2019.08.025","article-title":"Twelve years of pneumococcal conjugate vaccination in the Netherlands: impact on incidence and clinical outcomes of invasive pneumococcal disease","volume":"37","author":"Vestjens","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0265","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1016\/j.vaccine.2021.02.030","article-title":"Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland","volume":"39","author":"Polkowska","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0270","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01766-18","article-title":"Vaccination of Icelandic children with the 10-valent pneumococcal vaccine leads to a significant herd effect among adults in Iceland","volume":"57","author":"Quirk","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.065_b0275","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01046-18","article-title":"Effect of vaccination on pneumococci isolated from the Nasopharynx of healthy children and the middle Ear of children with otitis Media in Iceland","volume":"56","author":"Quirk","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.03.065_b0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-016-0755-7","article-title":"Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis","volume":"14","author":"Alari","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2024.03.065_b0285","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s10096-021-04196-4","article-title":"Effect of childhood pneumococcal vaccination and beta-lactam antibiotic use on the incidence of invasive pneumococcal disease in the adult population","volume":"40","author":"Ch\u00e1vez","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0290","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2014.05.020","article-title":"Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine","volume":"80","author":"Mendes","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2024.03.065_b0295","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1128\/AAC.00182-15","article-title":"Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012","volume":"59","author":"Mendes","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2024.03.065_b0300","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2169\/internalmedicine.54.3845","article-title":"Changes in the distribution of Capsular serotypes of Streptococcus pneumoniae isolated from adult respiratory specimens in Japan","volume":"54","author":"Shoji","year":"2015","journal-title":"Intern Med"},{"key":"10.1016\/j.vaccine.2024.03.065_b0305","doi-asserted-by":"crossref","first-page":"15843","DOI":"10.1038\/srep15843","article-title":"Evolving pneumococcal serotypes and sequence types in relation to high antibiotic stress and conditional pneumococcal immunization","volume":"5","author":"Su","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2024.03.065_b0310","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2024.03.065_b0315","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1016\/j.vaccine.2020.04.048","article-title":"Increasing non-susceptibility to antibiotics within carried pneumococcal serotypes - Alaska, 2008\u20132015","volume":"38","author":"Plumb","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.03.065_b0320","article-title":"Strategic Advisory Group of Experts (SAGE) Evidence to recommendation framework: Pneumococcal Conjugate Vaccine PICO 2: Product Choice","year":"2017","journal-title":"Impact"},{"key":"10.1016\/j.vaccine.2024.03.065_b0325","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24003712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T06:37:36Z","timestamp":1731652656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24003712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24003712"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.03.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}